The global Immuno-Oncology (I-O) therapeutics and Antibody-Drug Conjugates (ADCs) Market is entering a phase of rapid, transformative expansion, driven by breakthroughs in targeted therapies and combination regimens. The market, valued at USD 11.88 billion in 2024, is projected to surge to USD 34.12 billion by 2032. https://www.databridgemarketresearch.com/